Confo Therapeutics, a spin-off of VUB and VIB and a leader in the discovery of medications that target G-protein coupled receptors (GPCRs), announced a worldwide licensing agreement with Eli Lilly and Company for their clinical-stage compound CFTX-1554 and related backup compounds.
CFTX-1554 provides a non-opioid alternative for treating neuropathic pain, a debilitating condition caused by damage to nerves outside the brain and spinal cord. Current treatment options are often inadequate and can result in severe side effects such as addiction, making effective analgesics that do not affect quality of life an urgent need for patients with peripheral pain.
CFTX-1554 is presently in Phase 1 clinical trials, and Lilly will be continuing the clinical development process beyond this stage as part of the agreement. The deal also includes a program to further develop Confo's current therapeutic antibody candidates that target the same receptor.